Contact
searchSearch
HMP Global

Follicular Lymphoma Topic Center

News
Older Adult Data Underreported in DLBCL Registration Trials Worldwide
03/18/2026
Hannah Musick
A systematic review of diffuse large B-cell lymphoma (DLBCL) registration trials found that while most primary outcomes are reported for older adults, key data on secondary endpoints, toxicity, and quality of life remain largely missing,...
A systematic review of diffuse large B-cell lymphoma (DLBCL) registration trials found that while most primary outcomes are reported for older adults, key data on secondary endpoints, toxicity, and quality of life remain largely missing,...
A systematic review of diffuse...
03/18/2026
First Report Managed Care
News
Fixed-Duration Epcoritamab Plus R2 Shows Strong Outcomes in R/R Follicular Lymphoma
03/17/2026
Grace Taylor, MS, MA
Fixed-duration epcoritamab combined with rituximab plus lenalidomide (R2) delivers high complete response rates and durable remissions in relapsed or refractory (R/R) follicular lymphoma, according to a study published in Blood.
Fixed-duration epcoritamab combined with rituximab plus lenalidomide (R2) delivers high complete response rates and durable remissions in relapsed or refractory (R/R) follicular lymphoma, according to a study published in Blood.
Fixed-duration epcoritamab...
03/17/2026
First Report Managed Care
News
Single Bispecific Antibody Use May Reduce Costs and Streamline Lymphoma Care
03/12/2026
Lisa Kuhns, PhD, MD
A single bispecific antibody used across multiple lymphoma indications could save oncology practices hundreds of thousands of dollars and thousands of staff hours annually, according to a new mixed-methods analysis published in Future...
A single bispecific antibody used across multiple lymphoma indications could save oncology practices hundreds of thousands of dollars and thousands of staff hours annually, according to a new mixed-methods analysis published in Future...
A single bispecific antibody...
03/12/2026
First Report Managed Care
News
Epcoritamab Shows Superior Responses vs Chemoimmunotherapy in Relapsed Follicular Lymphoma
03/11/2026
Hannah Musick
In an indirect comparison of third-line or later follicular lymphoma, epcoritamab demonstrated significantly higher response rates vs chemoimmunotherapy and favorable safety compared with other bispecific antibodies.
In an indirect comparison of third-line or later follicular lymphoma, epcoritamab demonstrated significantly higher response rates vs chemoimmunotherapy and favorable safety compared with other bispecific antibodies.
In an indirect comparison of...
03/11/2026
First Report Managed Care
News
GLOBIN Study Reports Promising First-Line Outcomes in Follicular Lymphoma
03/06/2026
Grace Taylor, MS, MA
First-line glofitamab plus obinutuzumab (GLOBIN) achieved a 100% response rate with manageable toxicity in patients with high-tumor burden follicular lymphoma, according to a phase II multicenter trial presented at the ASH Annual Meeting and...
First-line glofitamab plus obinutuzumab (GLOBIN) achieved a 100% response rate with manageable toxicity in patients with high-tumor burden follicular lymphoma, according to a phase II multicenter trial presented at the ASH Annual Meeting and...
First-line glofitamab plus...
03/06/2026
First Report Managed Care
News
Outpatient Management of Grade 1 CRS Safe in R/R Follicular Lymphoma
03/05/2026
Hannah Musick
In a multicenter US cohort of patients with relapsed or refractory (R/R) follicular lymphoma, grade 1 cytokine release syndrome (CRS) following bispecific antibody therapy was safely managed in the outpatient setting without compromising...
In a multicenter US cohort of patients with relapsed or refractory (R/R) follicular lymphoma, grade 1 cytokine release syndrome (CRS) following bispecific antibody therapy was safely managed in the outpatient setting without compromising...
In a multicenter US cohort of...
03/05/2026
First Report Managed Care
News
Enhancing Prediction of Long-Term Survival After CAR T in DLBCL
03/05/2026
Hannah Musick
In a single-center US cohort of patients with diffuse large B-cell lymphoma (DLBCL), achieving event-free survival at 12 months after CAR T therapy was associated with durable remission and a 68% 5-year progression-free survival rate.
In a single-center US cohort of patients with diffuse large B-cell lymphoma (DLBCL), achieving event-free survival at 12 months after CAR T therapy was associated with durable remission and a 68% 5-year progression-free survival rate.
In a single-center US cohort of...
03/05/2026
First Report Managed Care
News
Long-Term SWOG Trial Data Suggest Cure Possible in Advanced Follicular Lymphoma
03/02/2026
Grace Taylor, MS, MA
A 15-year follow-up from the SWOG S0016 trial suggests that CHOP-based chemoimmunotherapy can achieve durable remission—and potential cure—in a substantial subset of patients with advanced-stage follicular lymphoma.
A 15-year follow-up from the SWOG S0016 trial suggests that CHOP-based chemoimmunotherapy can achieve durable remission—and potential cure—in a substantial subset of patients with advanced-stage follicular lymphoma.
A 15-year follow-up from the...
03/02/2026
First Report Managed Care
News
Epcoritamab Plus Lenalidomide and Rituximab Improves PFS in Relapsed Follicular Lymphoma
02/23/2026
Grace Taylor, MS, MA
In the phase 3 EPCORE FL-1 trial, adding epcoritamab to lenalidomide and rituximab significantly improved response rates and reduced the risk of progression or death by 79% versus R2 alone, positioning the chemotherapy-free triplet as a...
In the phase 3 EPCORE FL-1 trial, adding epcoritamab to lenalidomide and rituximab significantly improved response rates and reduced the risk of progression or death by 79% versus R2 alone, positioning the chemotherapy-free triplet as a...
In the phase 3 EPCORE FL-1...
02/23/2026
First Report Managed Care
News
Real-World Analysis of First-Line Treatment Outcomes in Follicular Lymphoma
05/09/2025
Juliet Gallagher
A recent retrospective analysis of real-world data published in Clinical Lymphoma, Myeloma, and Leukemia, evaluated treatment outcomes in patients with follicular lymphoma (FL) grades 1-3A receiving frontline bendamustine plus rituximab (BR)...
A recent retrospective analysis of real-world data published in Clinical Lymphoma, Myeloma, and Leukemia, evaluated treatment outcomes in patients with follicular lymphoma (FL) grades 1-3A receiving frontline bendamustine plus rituximab (BR)...
A recent retrospective analysis...
05/09/2025
First Report Managed Care
Industry Insights
News Conference Coverage
Expert Perspectives
Videos

What's New?

News
Older Adult Data Underreported in DLBCL Registration Trials Worldwide
03/18/2026
Hannah Musick
A systematic review of diffuse large B-cell lymphoma (DLBCL) registration trials found that while most primary outcomes are reported for older adults, key data on secondary endpoints, toxicity, and quality of life remain largely missing,...
A systematic review of diffuse large B-cell lymphoma (DLBCL) registration trials found that while most primary outcomes are reported for older adults, key data on secondary endpoints, toxicity, and quality of life remain largely missing,...
A systematic review of diffuse...
03/18/2026
First Report Managed Care
News
Fixed-Duration Epcoritamab Plus R2 Shows Strong Outcomes in R/R Follicular Lymphoma
03/17/2026
Grace Taylor, MS, MA
Fixed-duration epcoritamab combined with rituximab plus lenalidomide (R2) delivers high complete response rates and durable remissions in relapsed or refractory (R/R) follicular lymphoma, according to a study published in Blood.
Fixed-duration epcoritamab combined with rituximab plus lenalidomide (R2) delivers high complete response rates and durable remissions in relapsed or refractory (R/R) follicular lymphoma, according to a study published in Blood.
Fixed-duration epcoritamab...
03/17/2026
First Report Managed Care
News
Single Bispecific Antibody Use May Reduce Costs and Streamline Lymphoma Care
03/12/2026
Lisa Kuhns, PhD, MD
A single bispecific antibody used across multiple lymphoma indications could save oncology practices hundreds of thousands of dollars and thousands of staff hours annually, according to a new mixed-methods analysis published in Future...
A single bispecific antibody used across multiple lymphoma indications could save oncology practices hundreds of thousands of dollars and thousands of staff hours annually, according to a new mixed-methods analysis published in Future...
A single bispecific antibody...
03/12/2026
First Report Managed Care
News
Epcoritamab Shows Superior Responses vs Chemoimmunotherapy in Relapsed Follicular Lymphoma
03/11/2026
Hannah Musick
In an indirect comparison of third-line or later follicular lymphoma, epcoritamab demonstrated significantly higher response rates vs chemoimmunotherapy and favorable safety compared with other bispecific antibodies.
In an indirect comparison of third-line or later follicular lymphoma, epcoritamab demonstrated significantly higher response rates vs chemoimmunotherapy and favorable safety compared with other bispecific antibodies.
In an indirect comparison of...
03/11/2026
First Report Managed Care
News
GLOBIN Study Reports Promising First-Line Outcomes in Follicular Lymphoma
03/06/2026
Grace Taylor, MS, MA
First-line glofitamab plus obinutuzumab (GLOBIN) achieved a 100% response rate with manageable toxicity in patients with high-tumor burden follicular lymphoma, according to a phase II multicenter trial presented at the ASH Annual Meeting and...
First-line glofitamab plus obinutuzumab (GLOBIN) achieved a 100% response rate with manageable toxicity in patients with high-tumor burden follicular lymphoma, according to a phase II multicenter trial presented at the ASH Annual Meeting and...
First-line glofitamab plus...
03/06/2026
First Report Managed Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use